The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.

Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive background in healthcare policy and industry strategy, Tiffany offers invaluable insights into the practical implications of this landmark legislation for the pharmaceutical industry.

From dissecting the intricacies of price negotiation to unraveling the complexities of data collection requirements, this episode provides a clear roadmap for pharmaceutical companies and life sciences firms navigating the post-IRA era.

For more from our Value & Access experts, check out these insights:

BLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What’s Next 

Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies 

BLOG: What Can We Learn From ICER's New Value Framework 

Syneos Health Podcast | Market Access for Weight Loss Drugs 

MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts 

BLOG: What ICER’s Draft Sickle Cell Disease Report Means for CGT Pricing 

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.